BioSpace News Archive

Emerald Bioscience, Inc. today announced that the company has accepted an invitation to join the Alliance for Biosecurity. The Alliance, based in Washington, DC, is

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has received positive feedback from Health Canada on the Company’s plan to conduct a phase 2 COVID-19 clinical study in Canada, with its repurposed drug NP-120 (Ifenprodil).

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate and leukemia, today announced it will be presenting at the 19th Annual Needham Healthcare Conference at 3:30

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that its E-Commerce business segment experienced strong revenue growth, during its most recent completed quarter -- 4 th Fiscal Quarter

Mimeo, the global provider of online managed print and content distribution, is proud to help Intercept Pharmaceuticals execute critical training on drugs treating chronic diseases, despite the impact of the COVID-19 pandemic.

Cynosure, LLC, a leader in medical aesthetics systems and technologies, announced today the appointment of David Long as the company’s Chief Financial Officer, effective immediately. With more than 25 years of global financ

With the consistently rising numbers of COVID-19, many healthcare systems are becoming quickly overwhelmed in their Emergency Departments, Med-Surge Units and ICU Units.

OSSIO, Inc., an orthopedic fixation company dedicated to improving orthopedic outcomes and experiences, today announced the appointment of Gary J. Pruden to its Board of Directors.

Akers Biosciences, Inc. , today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-Crypt TM platform at Prema

COLCORONA trial to examine whether colchicine can reduce complications associated with COVID-19, slow disease progression, and save patient lives